Association between estimated whole-brain radiofrequency electromagnetic fields dose and cognitive function in preadolescents and adolescents.


Journal

International journal of hygiene and environmental health
ISSN: 1618-131X
Titre abrégé: Int J Hyg Environ Health
Pays: Germany
ID NLM: 100898843

Informations de publication

Date de publication:
01 2021
Historique:
received: 16 01 2020
revised: 18 09 2020
accepted: 29 10 2020
pubmed: 23 11 2020
medline: 26 10 2021
entrez: 22 11 2020
Statut: ppublish

Résumé

To investigate the association between estimated whole-brain radiofrequency electromagnetic fields (RF-EMF) dose, using an improved integrated RF-EMF exposure model, and cognitive function in preadolescents and adolescents. Cross-sectional analysis in preadolescents aged 9-11 years and adolescents aged 17-18 years from the Dutch Amsterdam Born Children and their Development Study (n = 1664 preadolescents) and the Spanish INfancia y Medio Ambiente Project (n = 1288 preadolescents and n = 261 adolescents), two population-based birth cohort studies. Overall whole-brain RF-EMF doses (mJ/kg/day) were estimated for several RF-EMF sources together including mobile and Digital Enhanced Cordless Telecommunications phone calls (named phone calls), other mobile phone uses than calling, tablet use, laptop use (named screen activities), and far-field sources. We also estimated whole-brain RF-EMF doses in these three groups separately (i.e. phone calls, screen activities, and far-field) that lead to different patterns of RF-EMF exposure. We assessed non-verbal intelligence in the Dutch and Spanish preadolescents, information processing speed, attentional function, and cognitive flexibility in the Spanish preadolescents, and working memory and semantic fluency in the Spanish preadolescents and adolescents using validated neurocognitive tests. Estimated overall whole-brain RF-EMF dose was 90.1 mJ/kg/day (interquartile range (IQR) 42.7; 164.0) in the Dutch and Spanish preadolescents and 105.1 mJ/kg/day (IQR 51.0; 295.7) in the Spanish adolescents. Higher overall estimated whole-brain RF-EMF doses from all RF-EMF sources together and from phone calls were associated with lower non-verbal intelligence score in the Dutch and Spanish preadolescents (-0.10 points, 95% CI -0.19; -0.02 per 100 mJ/kg/day increase in each exposure). However, none of the whole-brain RF-EMF doses was related to any other cognitive function outcome in the Spanish preadolescents or adolescents. Our results suggest that higher brain exposure to RF-EMF is related to lower non-verbal intelligence but not to other cognitive function outcomes. Given the cross-sectional nature of the study, the small effect sizes, and the unknown biological mechanisms, we cannot discard that our resultsare due to chance finding or reverse causality. Longitudinal studies on RF-EMF brain exposure and cognitive function are needed.

Identifiants

pubmed: 33221634
pii: S1438-4639(20)30605-2
doi: 10.1016/j.ijheh.2020.113659
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

113659

Informations de copyright

Copyright © 2020 Elsevier GmbH. All rights reserved.

Auteurs

Alba Cabré-Riera (A)

ISGlobal, Doctor Aiguader 88, 08003, Barcelona, Spain; Pompeu Fabra University, Doctor Aiguader 88, 08003, Barcelona, Spain; Spanish Consortium for Research and Public Health (CIBERESP), Instituto de Salud Carlos III, Avenida de Monforte de Lemos 5, 28029, Madrid, Spain.

Luuk van Wel (L)

Institute for Risk Assessment Sciences (IRAS), Utrecht University, Yalelaan 2, 3584 CM Utrecht, the Netherlands.

Ilaria Liorni (I)

IT'IS Foundation, Zeughausstrasse 43, CH-8004 Zurich, Switzerland.

Arno Thielens (A)

Department of Information Technology, Ghent University/IMEC, Technologiepark 126, 9052, Gent, Belgium.

Laura Ellen Birks (LE)

ISGlobal, Doctor Aiguader 88, 08003, Barcelona, Spain; Pompeu Fabra University, Doctor Aiguader 88, 08003, Barcelona, Spain; Spanish Consortium for Research and Public Health (CIBERESP), Instituto de Salud Carlos III, Avenida de Monforte de Lemos 5, 28029, Madrid, Spain.

Livia Pierotti (L)

ISGlobal, Doctor Aiguader 88, 08003, Barcelona, Spain; Pompeu Fabra University, Doctor Aiguader 88, 08003, Barcelona, Spain; Spanish Consortium for Research and Public Health (CIBERESP), Instituto de Salud Carlos III, Avenida de Monforte de Lemos 5, 28029, Madrid, Spain.

Wout Joseph (W)

Department of Information Technology, Ghent University/IMEC, Technologiepark 126, 9052, Gent, Belgium.

Llúcia González-Safont (L)

Spanish Consortium for Research and Public Health (CIBERESP), Instituto de Salud Carlos III, Avenida de Monforte de Lemos 5, 28029, Madrid, Spain; Epidemiology and Environmental Health Joint Research Unit, FISABIO-Universitat Jaume I-Universitat de València, Avinguda de Cataluya 21, 46020 Valencia, Spain.

Jesús Ibarluzea (J)

Spanish Consortium for Research and Public Health (CIBERESP), Instituto de Salud Carlos III, Avenida de Monforte de Lemos 5, 28029, Madrid, Spain; Department of Health, Public Health Division of Gipuzkoa, 20014, San Sebastian, Spain; BIODONOSTIA Health Research Institute, Avenida de Navarra 4, 20013, San Sebastian, Spain; Faculty of Psychology, University of the Basque Country (UPV/EHU), Berio Pasealekua, 20018, San Sebastian, Spain.

Amparo Ferrero (A)

Spanish Consortium for Research and Public Health (CIBERESP), Instituto de Salud Carlos III, Avenida de Monforte de Lemos 5, 28029, Madrid, Spain; Epidemiology and Environmental Health Joint Research Unit, FISABIO-Universitat Jaume I-Universitat de València, Avinguda de Cataluya 21, 46020 Valencia, Spain.

Anke Huss (A)

Institute for Risk Assessment Sciences (IRAS), Utrecht University, Yalelaan 2, 3584 CM Utrecht, the Netherlands.

Joe Wiart (J)

LTCI, Telecom Paris, Chaire C2M France, 19 Place Marguerite Perey, 91120, Palaiseau, France.

Loreto Santa-Marina (L)

Spanish Consortium for Research and Public Health (CIBERESP), Instituto de Salud Carlos III, Avenida de Monforte de Lemos 5, 28029, Madrid, Spain; Department of Health, Public Health Division of Gipuzkoa, 20014, San Sebastian, Spain; BIODONOSTIA Health Research Institute, Avenida de Navarra 4, 20013, San Sebastian, Spain.

Maties Torrent (M)

ib-Salut, Area de Salud de Menorca, Carrer Sant Josep 5, 07720, Santa Ana, Spain.

Tanja Vrijkotte (T)

Department of Public and Occipational Health, Amsterdam Public Health Research Institute, Amsterdam University Medical Center, University of Amsterdam, Meibergdreef 9, 1105AZ, Amsterdam, the Netherlands.

Myles Capstick (M)

IT'IS Foundation, Zeughausstrasse 43, CH-8004 Zurich, Switzerland.

Roel Vermeulen (R)

Institute for Risk Assessment Sciences (IRAS), Utrecht University, Yalelaan 2, 3584 CM Utrecht, the Netherlands.

Martine Vrijheid (M)

ISGlobal, Doctor Aiguader 88, 08003, Barcelona, Spain; Pompeu Fabra University, Doctor Aiguader 88, 08003, Barcelona, Spain; Spanish Consortium for Research and Public Health (CIBERESP), Instituto de Salud Carlos III, Avenida de Monforte de Lemos 5, 28029, Madrid, Spain.

Elisabeth Cardis (E)

ISGlobal, Doctor Aiguader 88, 08003, Barcelona, Spain; Pompeu Fabra University, Doctor Aiguader 88, 08003, Barcelona, Spain; Spanish Consortium for Research and Public Health (CIBERESP), Instituto de Salud Carlos III, Avenida de Monforte de Lemos 5, 28029, Madrid, Spain.

Martin Röösli (M)

Departement of Epidemiology and Public Health, Swiss Tropical and Public Health Institute, Socinstrasse 57, 4051, Basel, Switzerland; University of Basel, Petersplatz 1, 4051, Basel, Switzerland.

Mònica Guxens (M)

ISGlobal, Doctor Aiguader 88, 08003, Barcelona, Spain; Pompeu Fabra University, Doctor Aiguader 88, 08003, Barcelona, Spain; Spanish Consortium for Research and Public Health (CIBERESP), Instituto de Salud Carlos III, Avenida de Monforte de Lemos 5, 28029, Madrid, Spain; Department of Child and Adolescent Psychiatry/Psychology, Erasmus MC, University Medical Centre, Dr. Molenwaterplein 50, 3015GE, Rotterdam, the Netherlands. Electronic address: monica.guxens@isglobal.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH